c-Myc inhibitor 10

C-Myc Inhibitor 10 (compound 17), exhibiting enhanced cellular potency, benefits from increased permeability due to the methylation of the morpholine nitrogen [1].

c-Myc Peptide Trifluoroacetate is a synthetic peptide corresponding to the C-terminal amino acids (410-419) of human c-myc protein. c-Myc Peptide Trifluoroacetate participates in regulation of growth-related gene transcription.

C-Met inhibitor D9 is a c-Met kinase inhibitor.

MINA53 inhibitor (Compound 10) is an inhibitor of MINA53.

C-MYC PEPTIDE EPITOPE TFA, the product of the c-myc proto-oncogene, is a helix-loop-helix leucine zipper phosphoprotein that regulates gene transcription in cell proliferation, cell differentiation and apoptosis. This peptide is a human c-myc epitope.

C-Myc Inhibitor 7, serving as both a c-Myc inhibitor and a multi-target protein degrader, effectively degrades proteins c-MYC, CK1α, GSPT1, and IKZF1/2/3 across various tumor cell types. It holds potential for research into diseases associated with high c-Myc expression, including cancer, cardiovascular and cerebrovascular conditions, and viral infections.

Tuberculosis Inhibitor 10 moderately inhibits the enzyme MSMEG_6649 and potentiates the antimycobacterial activity of PAS [1].

BRD4 Inhibitor-10 is an inhibitor of BRD4-BD1 (IC50: 8 nM).

Compound 13, a topoisomerase I inhibitor 10, selectively inhibits leishmanial topoisomerase IB and exhibits antileishmanial activity. Specifically, it demonstrates efficacy against L. donovani promastigotes with an IC50 value of 27.91 μM [1].

c-Myc Peptide is a useful displacement of c-Myc-tagged fusion proteins bound to anti-c-Myc antibodies in immunoassays. The successful inhibition of antibody binding by c-Myc peptide demonstrates binding is specific. c-Myc peptide participates in the regul

KRAS G12D Inhibitor 10 is a potent agent targeting the KRAS G12D mutation, a variant in the Ras protein family crucial for cellular growth and development. This compound shows promise for investigating cancers mediated by KRAS G12D.

C-Myc Inhibitor 8 is an effective compound for cancer research, inhibiting cell viability across a range of cancer types and demonstrating growth suppression in human prostate and lung cancers within mouse models. This inhibitor specifically targets the c-Myc pathway, showcasing its potential utility in oncological studies.

FSH receptor-binding inhibitor fragment (bi-10) is a potent antagonist that inhibits the binding of follicle-stimulating hormone (FSH) to its receptor (FSHR), modifying FSH activity at the receptor level. It suppresses ovulation and induces follicular atresia in mice. Furthermore, this compound holds potential for curbing ovarian cancer carcinogenesis by reducing the overexpression of FSHR and estrogen receptor beta (ERβ) in the ovaries [1].

CypD inhibitor C-9 is a CypD inhibitor, it attenuates mitochondrial and cellular perturbation insulted by Aß and calcium stress.

c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.

Bromodomain inhibitor-10 (compound 128) is a highly potent inhibitor of bromodomain activity. It exhibits strong binding affinity with K d values of 15.0 nM and 2500 nM for BRD4-1 and BRD4-2, respectively. Furthermore, Bromodomain inhibitor-10 effectively inhibits the production of IL12p40 [1].

HIV-1 Integrase Inhibitor 10, an orally active allosteric integrase inhibitor (ALLINI), effectively inhibits the NLRepRluc virus's viral outgrowth in MT-2 cells, exhibiting EC50 values of 3-5 nM. This compound is utilized in the research of Human Immunodeficiency Virus-1 (HIV-1).

c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, a kinase inhibitor of FMS (Colony-stimulating factor-1 receptor, CSF-1R; IC50: 2 nM) with anti-tumor activity.

GSK-3β inhibitor 10 has skin-whitening, anti-oxidizing and PPAR activities.

BTK inhibitor 10 is a potent and orally active BTK inhibitor. It has the potential for rheumatoid arthritis treatment.

ATX inhibitor 10 is a nitrogen-containing heterocyclic compound that is a potent inhibitor of ATX. Among other things, ATX plays a role in causing pathologies including fibrosis, neurodegeneration, arthritis, neuropathic pain, and cancer. ATX inhibitor 10 has shown research potential for ATX-related diseases.

c-Myc inhibitor 4 is a potent, orally active c-Myc-reducing compound. c-Myc is an important proto-oncogene, which is closely associated with the development of many tumors.

FGFR1 inhibitor-10 (Compound 4i), with an IC50 of 28 nM, effectively inhibits FGFR1 phosphorylation. This compound demonstrates anti-angiogenic and anti-invasion properties, as well as a significant anti-tumor effect [1].

KRAS inhibitor-10 (WO2021005165 A1, compound 11) is a potent and selective inhibitor of RAS proteins, with a specific focus on KRAS proteins. This orally active anti-cancer agent demonstrates strong efficacy in cancer research, specifically in pancreatic cancer, breast cancer, multiple myeloma, leukemia, and lung cancer. KRAS inhibitor-10 is classified as a tetrahydroisoquinoline compound. Its inhibitory properties provide valuable insights and potential therapeutic applications in the field of oncology [1].

HIV-1 inhibitor-10 is a nanomolar HIV-1 maturation inhibitor.

c-Myc Inhibitor 5 (DA3) is a fluorescent bispurine compound with a long-chain bridge that selectively binds to the c-MYC G-quadruplex, exhibiting a dissociation constant (K D) of 16 μM. Unlike other G4-driven oncogenes, this inhibitor specifically suppresses c-MYC expression [1].

Chitin Synthase Inhibitor 10, as a potent chitin synthase inhibitor, exhibits remarkable inhibitory activity with an IC50 of 0.11 mM. It also functions as an antifungal agent, demonstrating substantial effectiveness against drug-resistant fungi, including C. albicans and C. neoformans. The compound is useful in researching invasive fungal infections (IFIs) [1].

Aurora kinase inhibitor-10 is an orally active Aurora B inhibitor (IC50: 8 nM) that exhibits antitumour effects.

Topoisomerase II inhibitor 10 is a potent inhibitor of topoisomerase II (IC50: 7.45 μM). Topoisomerase II inhibitor 10 was able to arrest the cell cycle of HepG-2 cells in the G2-M phase and induce apoptosis.

NFAT:AP-1 inhibitor-10 is a novel inhibitor of the NFAT:AP-1:DNA interaction on the ARRE-2 element, binding to DNA in a sequence-selective manner and inhibiting the transcription of the Il2 gene and several other cyclosporin A-sensitive cytokine genes important for the effector immune response.

PI3K inhibitor C 96 is an inhibitor of phosphatidylinositol 3-kinase. It shows effective activity against multiple myeloma in vitro and in vivo.

ENPP1 inhibitor C is an inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1; IC50 = 0.26 μM in a cell-free assay).1 It is selective for ENPP1 over ENPP2-7 at 10 μM. ENPP1 inhibitor C decreases ENPP1 activity in MDA-MB-231 human breast and C6 rat glioma cancer cells when used at a concentration of 10 μM. |1. Kawaguchi, M., Han, X., Hisada, T., et al. Development of an ENPP1 fluorescence probe for inhibitor screening, cellular imaging, and prognostic assessment of malignant breast cancer. J. Med. Chem. 62(20), 9254-9269 (2019).

C-HEGA-10 is a useful organic compound for research related to life sciences. The catalog number is TF0012 and the CAS number is 864434-15-1.

c-Myc Inhibitor 9 (Compound 332) is an effective c-Myc inhibitor, exhibiting a logEC50 of ≥6, and demonstrating significant tumor growth inhibition in nude mouse models. This compound is utilized in cancer research.

iNOS Inhibitor-10, with an IC50 of 65 nM, exhibits antiproliferative effects on triple-negative breast cancer cells [1].

7-Xylosyl-10-deacetyltaxol C is a natural product from Taxus wallichiana Zucc.

c-Myc inhibitor 11 (Compound 67e), a c-MYC inhibitor (p EC 50 : 6.4), exhibits high clearance, a moderate volume of distribution, and a short half-life in rat pharmacokinetic assays, making it suitable for cancer research [1].

Compound 67h, also known as c-Myc inhibitor 12, is a potent inhibitor of c-Myc, exhibiting a pEC50 value of 6.4 [1].

Glutaminase C Inhibitor 11 is a potent inhibitor specifically targeting Glutaminase C (GAC), demonstrating significant inhibition of GAC enzyme activity with an EC50 value of 10.64 nM. It effectively diminishes the viability of A549 non-small cell lung cancer (NSCLC) cells, presenting an IC50 of 4.025 nM. Moreover, at concentrations of 0.1 and 1 µM, it substantially impedes colony formation and reduces intracellular glutamate levels in A549 cells. Demonstrating efficacy in vivo, Glutaminase C Inhibitor 11 at a dosage of 100 mg/kg markedly curtails tumor growth in an A549 mouse xenograft model.

c-Met-IN-10 is a potent c-Met kinase inhibitor (IC50: 16 nM). c-Met-IN-10 inhibits the activity of cancer cells A549, H460 and HT-29, and inhibits A549 cell movement by inhibiting HT-29 cell colony formation, which in turn induces apoptosis in HT-29 and A549 cells. c-Met-IN-10 can be used in anticancer studies. -Met-IN-10 is capable of being used in anticancer studies.

Hepatitis Virus C NS3 Protease Inhibitor 2 is a peptide inhibitor derived from a product that targets the NS3 protease of the hepatitis C virus (HCV). Its inhibitory activity against the NS3 protease is characterized by a Ki value of 41 nM.

Carbonic anhydrase inhibitor 10 can be used in the research of cancer that shows anti-proliferative activity against MCF-7 cancer cell line with an IC50 of 11.9 μM. Carbonic anhydrase inhibitor 10 is a potent inhibitor of h CA IX with a Ki value of 6.2 nM [1].